Fulcrum Therapeutics: Buy It For The Strategic Reset
Fulcrum Therapeutics Inc FULC
$3.58
▼ -3.76%
($-0.14)
⚡ High Volume
🎢 High Beta
📅 Earnings This Week
Open
$3.72
Prev Close
$3.72
Day Range
$3.47 – $3.73
52W Range
$2.83 – $15.74
Market Cap
$238.55M
Beta
2.58
EPS (TTM)
$-0.90
📋 Company Profile
| Industry | Pharmaceuticals |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2019-07-18 |
| Shares Out. | 66,630,000 |
| Website | fulcrumtx.com/ ↗ |
| Phone | 16176518851 |
| Employees | 55 |
| Net Income | -$26.2M |
| Free Cash Flow | -$66.1M |
| Total Assets | $324.0M |
| Total Liabilities | $13.3M |
| Equity | $310.7M |
About Fulcrum Therapeutics Inc
Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing small molecules for genetically defined rare diseases. Its product candidate, Pociredir, is an oral small molecule designed to induce fetal hemoglobin (HbF) and is in clinical development for sickle cell disease (SCD). The company completed dosing in the Phase 1b PIONEER trial evaluating pociredir in adults with SCD and reported clinical data showing clinically relevant HbF induction and improvements in markers of hemolysis and anemia. The company has also generated a pipeline of clinical-stage and pre-clinical programs targeting the root causes of rare genetic diseases.
Fulcrum Therapeutics Inc is a publicly traded company under the ticker symbol FULC on the NASDAQ NMS - GLOBAL MARKET, operating in the Pharmaceuticals industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
13 analysts (2026-07-01)